NCT00491374终止4 期
A Double-Blind Placebo-Controlled, Randomized, Parallel-Group, Single-Site Study Of Mometasone Furoate Nasal Spray (MFNS) In Subjects With Mild-Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) Associated With Perennial Allergic Rhinitis (PAR) Using Polysomnographic Recordings of Sleep Parameters
Schering-Plough0 个研究点开始时间: 2006年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 主要终点
- The Change From Baseline in the Number of Apnea-hypopnea Episodes Per Hour (Apnea-hypopnea Index (AHI)
研究概览
简要总结
This study will hope to show that the treatment of the patient's perennial allergic rhinitis (PAR) using Nasonex® (mometasone furoate nasal spray) will result in improvement of the nasal symptoms of PAR and of nighttime sleep-disordered breathing, thereby resulting in improved sleep quality, less daytime sleepiness, improved daytime functioning, and improved quality of life.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be 18 to 45 years of age, of either sex, and any race.
- •Must have at least a 2-year history of PAR.
- •Must be skin test positive for the usual allergens associated with PAR within the previous 12 months with regular exposure to at least one of the allergens to which the subject is allergic.
- •Must be sufficiently symptomatic at the Screening Visit (Visit 1), Qualification Visit (Visit 2), and Baseline Visit (Visit 4) with a minimal level of PRIOR (reflective) total symptom score, total nasal symptoms score, and total non-nasal symptoms score in order to qualify.
- •At the Qualification Visit 2, subjects must have a score of at least 2 with the Interference with Sleep severity rating score for at least 3 of the 7 nights prior to the Qualification visit.
- •At the Baseline Visit 4 subjects must have a score of at least 2 with the Interference with Sleep severity rating score for at least 1 of the 3 nights prior to the Baseline Visit.
- •Must have an apnea-hypopnea index (AHI) of >=5, but not more than 30, during the first screening polysomnographic evaluation and to proceed to the second polysomnographic evaluation.
- •At the Baseline Visit (Visit 4), the subjects must complete the NRQLQ, PQSI, ESS, WPAI-AS.
- •Must complete the PVT within 1 hour of bedtime and 1 hour of arising on the nights when the PSGs are done.
- •Female subjects of childbearing potential (including women who are less than 1 year postmenopausal and women who will be sexually active during the study) must agree to use a medically accepted method of contraception or be surgically sterilized prior to screening, while receiving protocol-specified medication, and for 30 days after stopping the medication. Women who are postmenopausal for >1 year (ie, women who have experienced 12 consecutive months of amenorrhea) will be exempted from the use of contraception during the study.
- •Female subjects of childbearing potential must have a negative urine pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Visit 4 confirmed prior to dosing with the study drug and at final Visit 7.
排除标准
- •Subject has symptomatic seasonal allergic rhinitis (SAR) or a history of SAR during the same calendar period as this study.
- •Subject is a female who is pregnant, or intends to become pregnant during the study.
- •Subject is nursing, or intends to be nursing during the study.
- •Subject has used any investigational product within 30 days prior to enrollment or any antibodies for asthma or allergic rhinitis in the past 90 days).
- •Subject has any of the following clinical conditions:
- •known severe sleep apnea
- •chronic obstructive pulmonary disease (COPD)
- •alcohol abuse
- •rhinitis medicamentosa
- •Subject is currently on or has been on an antihistamine, decongestant (topical or systemic) or a nasal inhaled corticosteroid during the 14 days prior to the Screening Visit.
- •Subject with current or history of frequent episodes (2 or more episodes per year for the past 2 years) of clinically significant sinusitis or chronic purulent postnasal drip.
- •Subject has had recent nasal septum ulcers, nasal surgery, or nasal trauma.
- •Subject has had an upper or lower respiratory tract or sinus infection that required antibiotic therapy with the last dose 14 days prior to screening, or who has had a viral upper or lower respiratory infection within 14 days prior to screening.
- •Subject has nasal structural abnormalities, including large nasal polyps, and marked septum deviation that significantly interfere with nasal airflow.
- •Subject is unable to refrain from regular use of nasal, oral or ocular decongestants, nasal topical antihistamines, or nasal steroids.
- •Subject on immunotherapy (desensitization therapy) should not receive an increase in dose during the study. Subjects may not receive desensitization treatment within 24 hours prior to a study visit.
- •Subject has active or quiescent tuberculosis infection of the respiratory tract, untreated fungal, bacterial, or systemic viral infections, or ocular herpes simplex.
- •Subject is morbidly obese (BMI >=35).
- •Subject is a night-shift worker and does not have a standard asleep at night / awake during the day cycle, or has an irregular sleep/wake schedule.
- •Subject reports routinely spending less than 6 1/2 hours of time in bed per night.
- •Subject reports drinking 3 or more cups of regular coffee or 4 or more 8 ounce cans/bottles of caffeine-containing carbonated beverages per 24 hour period.
研究组 & 干预措施
MFNS
Experimental
干预措施: Mometasone Furoate Nasal Spray (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
The Change From Baseline in the Number of Apnea-hypopnea Episodes Per Hour (Apnea-hypopnea Index (AHI)
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic RhinitisAllergic RhinitisNCT01033396Pfizer64
已完成
4 期
Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)Seasonal Allergic RhinitisNCT00358527Organon and Co401
已完成
3 期
Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic RhinitisAllergic RhinitisNCT04264637Bayer110
已完成
2 期
Efficacy and Safety Study of BLX-028914 in Subjects With Allergic RhinitisAllergic RhinitisNCT00758446Dart NeuroScience, LLC36
已完成
2 期
Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge ChamberRhinitis, Allergic, SeasonalSeasonal Allergic RhinitisNCT00430157GlaxoSmithKline45